Blood test study for scleroderma-related lung complications
Part of Lungs & breathing, Skin clinical trials.
This study looks at tiny particles in your blood to see if they can predict whether you might develop a serious lung condition called pulmonary arterial hypertension (high blood pressure in the lungs). It aims to find better ways to detect and manage this complication early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old
- You have been diagnosed with systemic sclerosis (scleroderma)
- You are at high risk for pulmonary arterial hypertension based on a special screening tool
- You have been on stable treatment for your condition for at least 3 months
- You have not been previously diagnosed with pulmonary arterial hypertension
- You do not have significant lung scarring (interstitial lung disease) or severe heart failure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at whether a protein in your blood called catestatin can help doctors see how scleroderma is affecting your heart and small blood vessels. If you have scleroderma, joining could help doctors better monitor the disease and its effects.
This study follows adults with systemic scleroderma (also called scleroderma) to better understand the condition over time. You may be included if you meet specific diagnosis and blood-test requirements and can give informed consent.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
This trial tests whether sildenafil can improve early “high pressure in the lung blood vessels” in people with scleroderma. It may help slow worsening breathing and lung blood-vessel disease before it becomes severe.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.